The serine-threonine kinase AKT1 is a central player in the oncogenic pathway controlled by PI3K. Recently, a somatic mutation in AKT1 (E17K) has been detected in breast, colorectal, lung and ovarian cancers. The E17K change results in constitutive AKT1 activation and induces leukaemia in mice. We determined the occurrence of the E17K variant in a panel of 764 tumour samples. These included breast, lung, ovarian, colorectal and pancreatic carcinomas as well as melanomas and glioblastomas. Despite the fact that these tumours are known to bear alterations in genes involved in the PI3K signalling pathway, AKT1
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E17K was detected only in breast (16/273), colorectal (1/88) and lung (1/155) cancers. Within the neoplasms of breast origin, the AKT1 E17K variant was mutually exclusive with respect to the PIK3CA E454K or H1047R alleles and was present only in ductal and lobular histotypes. Our results, showing that AKT1 mutations seem to occur in a tissue-specific fashion have basic and clinical implications. First, the activity of mutated AKT1 in oncogenic PI3K signalling could be strictly dependent on the cell and tissue milieu. Second, therapeutic efforts aimed at selective targeting the AKT1 E17K variant could be effective mainly in specific cancer types. Oncogene (2008) 27, 5648-5650; doi:10.1038 /onc.2008 published online 26 May 2008 Keywords: AKT1; PIK3CA; mutation; cancer The molecular profiling of the tumour genome has provided a comprehensive list of mutated cancer genes and the signalling pathways they control. Among other findings these efforts have led to the discovery that the PI3K pathway is more frequently activated by genomic aberrations than any other signalling pathway in many tumour types (Brugge et al., 2007; Wood et al., 2007) . Dominant mutations affecting key nodes of the pathway represent potential therapeutic targets and, consequently, multiple efforts to inhibit deregulated PI3K signalling are under way. The lipid kinase PIK3CA and the phosphatase PTEN act as central regulators of this pathway by controlling the cellular levels of phosphatidylinositol-3-phosphate. PIK3CA is mutated in many tumour types, including breast, colon, endometrial and gastric, liver and ovary cancer (Samuels et al., 2004; Karakas et al., 2006) . The corresponding mutations result in activation of the PI3K catalytic activity and constitutive downstream signalling. The tumour suppressor gene PTEN counteracts the effect of PI3K and acts as a negative regulator of PI3K signalling. PTEN is mutationally and transcriptionally inactivated in many different tumour types, including glioblastoma multiforme (GBM), breast and prostate cancer (Li et al., 1997) . In most tumour lineages PIK3CA and PTEN mutations occur in a mutually exclusive manner (Frattini et al., 2005; Saal et al., 2005) , suggesting that they exert overlapping cellular functions.
Although most members of the phosphatidylinositol-3-kinase pathway are genetically altered in tumours, mutations in AKT1, a master regulator of the PI3K downstream signalling route, have long remained elusive (Brugge et al., 2007) . However, a recent sequencing effort has led to the identification of oncogenic somatic mutations in the pleckstrin homology domain (PHD) of AKT1. The AKT1 E17K mutation alters the electrostatic interactions of the pocket, activates AKT1 in a PI3K-independent manner, transforms rodent cells in vitro and can induce leukaemia in mice (Carpten et al., 2007) . Until now AKT1 mutations have been reported in breast, colon, ovarian and lung cancer (Carpten et al., 2007; Malanga et al., 2008) . Interestingly, in all the cases examined only one change (E17K) was detected. The tumour datasets analysed until now have been relatively small and the reported frequencies are generally low (5/61 breast, 3/51 colon, 1/50 ovarian and 3/105 lung) (Carpten et al., 2007; Malanga et al., 2008) . The status of the AKT1 E17K mutation in larger tumour sets and in additional cancer types remains to be determined (Brugge et al., 2007) .
In light of the potential relevance of oncogenic AKT as a therapeutic target, we determined the occurrence of the E17K variant in a panel of 764 tumour samples. These included 273 breast cancer, 88 colon cancer, 135 GBM, 155 lung cancer, 21 melanoma, 80 ovarian cancer and 12 pancreatic ductal adenocarcinoma (PDAC) samples (Table 1) . These tumour lineages were selected as they are known to carry alterations in the PI3K pathway at high (breast, colon, GBM and ovary), intermediate (lung) and low (melanoma and PDAC) frequency (Guldberg et al., 1997; Samuels et al., 2004; Schonleben et al., 2006) .
Primers were designed to amplify and sequence the genomic region corresponding to AKT1 exon 4, which encodes E17K and includes 15 intronic bases at the 5 0 and 3 0 ends encompassing the splicing donor and acceptor sites. A total of 764 PCR products, spanning 325 kb of tumour genomic DNA, were generated and subjected to direct sequencing. The AKT1 E17K mutation was identified 18 times, corresponding to an overall mutation frequency of 2.4%. Interestingly, AKT1 E17K was only found in breast (6%), colon (1%) and lung cancer (1%). None of the other human solid tumour types displayed the AKT1 E17K variant or any other change neighbouring this mutation in the AKT1 pleckstrin homology domain. Due to the limited number of melanoma and pancreatic samples examined, for these tumour types the results did not reach statistical significance. Our data strongly suggest that the prevalence of the AKT1 E17K allele is tissue specific in solid cancers occurring mainly in breast tumours. As the latter consists of multiple histotypes, we wondered whether AKT1 mutations might be found preferentially in any of them. It is noteworthy that AKT1 E17K was only found in ductal and lobular (and not in mucinous and medullary) breast cancers, indicating that its occurrence may not only be cancer but also histotype related in tumours ( Table 2) . The observation appears to hold true in lung cancer were the AKT1 mutation was detected only once in squamous cell and not in adenocarcinoma samples. This is in accordance with a previous report (Malanga et al., 2008) .
The occurrence of AKT1 and PIK3CA mutations are thought to be mutually exclusive events (Carpten et al., 2007) as predicted if the two genes were acting in the same signalling pathway. We performed a mutational profiling of the PIK3CA mutation hotspots (exons 9 and 20) in our series of 273 breast tumours. To increase the sensitivity and the specificity of the analysis we used both SSCP and direct sequencing with concordant results (data not shown). PIK3CA and AKT1
E17K
mutations were found to occur in a mutual exclusive pattern with one exception (sample 99-I-16807). Careful analysis of the AKT1 sequence electropherogram obtained from this tumour showed that the peak corresponding to the mutation was minor as compared to its wild-type counterpart. This is consistent with occurrence of the AKT1 E17K variant only in a subpopulation of the tumour cells of this sample. Interestingly the analysis also revealed that in ductal and lobular breast tumours carrying wild-type PIK3CA alleles, the prevalence of the AKT1 E17K variant approaches 11%. When AKT1 and PIK3CA mutations are considered together, 32% of breast cancers display dominant activation of the PI3K pathway underscoring its relevance in the therapeutic control of this tumour lineage (Table 2) . (Balakrishnan et al., 2007; Barbareschi et al., 2007) . Primer sequences are available on request. In conclusion, our data indicate that the AKT1 E17K mutation likely displays a unique tissue-specific pattern in human cancer. The molecular basis of the tissue-and gender-specific occurrence of cancer mutations remains an unsettled issue whose solution will be relevant for basic and clinical cancer research (Benvenuti et al., 2008) . The tumour-specific occurrence of the AKT1 E17K variant might reflect the pattern of expression of the AKT1 transcript. Alternatively, it could indicate that PIK3CA and AKT1 E17K mutations exert different cellular activities. To answer this question the development of cellular or animal models will likely be necessary. In particular, it will be of interest to determine whether and to what extent the cellular activities of the AKT1 E17K variant parallels those of the PIK3CA E454K or H1047R alleles (Samuels et al., 2004) .
Overall our findings, suggesting a tumour-specific occurrence of AKT1 mutations, have implications for basic and clinical research. The activity of mutated AKT1 in oncogenic PI3K signalling might be strictly dependent on the cell background. Furthermore, therapeutic efforts aimed at selective targeting the AKT1 E17K variant could be effective mainly in breast cancers and in other cancer types sporadically carrying this allele.
